Abstract
1. The amyloid ß-peptide (Aß) is involved in the mechanisms of Alzheimer dementia. This paper reviews experimental evidence indicating that Aß exerts profound effects on the regulation of the cerebral circulation.
2. Thus, Aß compromises the ability of cerebral endothelial cells to produce vascular relaxing factors, impairs the ability of cerebral blood vessels to maintain adequate flow during hypotension, and attenuates the increases in CBF evoked by enhanced brain activity.
3. Studies in transgenic mice overexpressing the amyloid precursor protein suggest that these cerebrovascular alterations disrupt the delicate balance between the brain's energy requirements and cerebral blood supply, rendering the brain more vulnerable to ischemic injury.
4. The findings support the recently emerged notion that vascular factors play a pathogenic role in the early stages of Alzheimer dementia.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
Alonzo, N. C., Hyman, B. T., Rebeck, G. W., and Greenberg, S. M. (1998). Progression of cerebral amyloid angiopathy: Accumulation of amyloid-beta40 in affected vessels. J. Neuropathol. Exp. Neurol. 57:353–359.
Babior, B. M, Aji, W., Ravalli, S., Szabolcs, M., Jiang, X. C., Sciacca, R. R., Michler, R. E., and Cannon, P. J. (1999). NADPH oxidase: An update. Blood 93:1464–1476.
Behl, C., Davis, J. B., Lesley, R., and Schubert, D. (1994). Hydrogen peroxide mediates amyloid beta protein toxicity. Cell 77:817–827.
Bookheimer, S. Y., Strojwas, M. H., Cohen, M. S., Saunders, A. M., Pericak-Vance, M. A., Mazziotta, J. C., and Small, G. W. (2000). Patterns of brain activation in people at risk for Alzheimer's disease. N. Engl. J. Med. 343:450–456.
Braak, H., and Braak, E. (1991). Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. (Berl.) 82:239–259.
Brun, A., and Englund, E. (1986). A white matter disorder in dementia of the Alzheimer type: A pathoanatomical study. Ann. Neurol. 19:253–262.
Cai, H., Harrison, D. G., Rothe, G., and Valet, G. (2000). Endothelial dysfunction in cardiovascular diseases: The role of oxidant stress. Circ. Res. 87:840–844.
Crawford, F., Suo, Z., Fang, C., and Mullan, M. (1998). Characteristics of the in vitro vasoactivity of beta-amyloid peptides. Exp. Neurol. 150:159–168.
Faraci, F. M., and Heistad, D. D. (1998). Regulation of the cerebral circulation: Role of endothelium and potassium channels. Physiol. Rev. 78:53–97.
Games, D., Adams, D., Alessandrini, R., Barbour, R., Berthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., Gillespie, F., Guido, T., Hagopian, S., Johnson-Wood, K., Khan, K., Lee, M., Leibowitz, P., Lieberburg, I., Little, S., Masliah, E., McConlogue, L., Montoya-Zavala, M., Mucke, L., Paganini, L., and Penniman, E. (1995). Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 373:523–527.
Glenner, G. G., and Wong, C. W. (1984). Alzheimer's disease and Down's syndrome: Sharing of a unique cerebrovascular amyloid fibril protein. Biochem. Biophys. Res. Commun. 122:1131–1135.
Good, P. F., Werner, P., Hsu, A., Olanow, C. W., and Perl, D. P. (1996). Evidence of neuronal oxidative damage in Alzheimer's disease. Am. J. Pathol. 149:21–28.
Griendling, K. K., Minieri, C. A., Ollerenshaw, J. D., and Alexander, R. W. (1994). Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ. Res. 74:1141–1148.
Hensley, K., Carney, J. M., Mattson, M. P., Aksenova, M., Harris, M., Wu, J. F., Floyd, R. A., and Butterfield, D. A. (1994). A model for beta-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: Relevance to Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 91:3270–3274.
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., and Cole, G. (1996). Correlative memory deficits, Aelevation, and amyloid plaques in transgenic mice. Science 274:99–102.
Hsiao, K. K., Borchelt, D. R., Olson, K., Johannsdottir, R., Kitt, C., Yunis, W., Xu, S., Eckman, C., Younkin, S., Price, D., Iadecola, C., Clark, H. B., and Carlson, G. (1995). Age-related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor proteins. Neuron 15:1203–1218.
Iadecola, C., Zhang, F., Niwa, K., Eckman, C., Turner, S. K., Fischer, E., Younkin, S., Borchelt, D. R., Hsiao, K. K., and Carlson, G. A. (1999). SOD1 rescues cerebral endothelial dysfunction in mice overexpressing amyloid precursor protein. Nat. Neurosci. 2:157–161.
Irizarry, M. C., McNamara, M., Fedorchak, K., Hsiao, K., and Hyman, B. T. (1997). APPSW transgenic mice develop age-related A beta deposits and neuropil abnormalities, but no neuronal loss in CA1. J. Neuropathol. Exp. Neurol. 56:965–973.
Jagust, W. J., Eberling, J. L., Reed, B. R., Mathis, C. A., and Budinger, T. F. (1997). Clinical studies of cerebral blood flow in Alzheimer's disease. Ann. N. Y. Acad. Sci. 826:254–262.
Jagust, W. J., Haan, M. N., Reed, B. R., and Eberling, J. L. (1998). Brain perfusion imaging predicts survival in Alzheimer's disease. Neurology 51:1009–1013.
Kalaria, R. N. (1996). Cerebral vessels in ageing and Alzheimer's disease. Pharmacol. Ther. 72:193–214.
Kawarabayashi, T., Younkin, L. H., Saido, T. C., Shoji, M., Ashe, K. H., and Younkin, S. G. (2001). Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J. Neurosci. 21:372–381.
Le, R., Cruz, L., Urbanc, B., Knowles, R. B., Hsiao-Ashe, K., Duff, K., Irizarry, M. C., Stanley, H. E., and Hyman, B. T. (2001). Plaque-induced abnormalities in neurite geometry in transgenic models of Alzheimer disease: Implications for neural system disruption. J. Neuropathol. Exp. Neurol. 60:753–758.
Lee, V. M., Goedert, M., and Trojanowski, J. Q. (2001). Neurodegenerative tauopathies. Annu. Rev. Neurosci. 24:1121–1159.
Levy-Lahad, E., and Bird, T. D. (1996). Genetic factors in Alzheimer's disease: A review of recent advances. Ann. Neurol. 40:829–840.
Loo, D. T., Copani, A., Pike, C. J., Whittemore, E. R., Walencewicz, A. J., and Cotman, C. W. (1993). Apoptosis is induced by beta-amyloid in cultured central nervous system neurons. Proc. Natl. Acad. Sci. U.S.A. 90:7951–7955.
Matsushita, K., Kuriyama, Y., Nagatsuka, K., Nakamura, M., Sawada, T., and Omae, T. (1994). Periventricular white matter lucency and cerebral blood flow autoregulation in hypertensive patients. Hypertension 23:565–568.
Mattson, M. P., Cheng, B., Davis, D., Bryant, K., Lieberburg, I., and Rydel, R. E. (1992). beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J. Neurosci. 12:376–389.
Mattson, M. P. (1997). Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives. Physiol. Rev. 77:1081–1132.
Mohazzab-H, K. M., Kaminski, P. M., and Wolin, M. S. (1994). NADH oxidoreductase is a major source of superoxide anion in bovine coronary artery endothelium. Am. J. Physiol. 266:H2568-H2572.
Niwa, K., Carlson, G. A., and Iadecola, C. (2000a). Exogenous A beta1–40 reproduces cerebrovascular alterations resulting from amyloid precursor protein overexpression in mice. J. Cereb. Blood Flow Metab. 20:1659–1668.
Niwa, K., Kazama, K., Younkin, S. G., Carlson, G. A., and Iadecola, C. (2002a). Alterations in cerebral blood flow and glucose utilization in mice overexpressing the amyloid precursor protein. Neurobiol. Dis. 9:61–68.
Niwa, K., Kazama, K., Younkin, L., Younkin, S. G., Carlson, G. A., and Iadecola, C. (2002b). Cerebrovascular autoregulation is profoundly impaired in mice overexpressing amyloid precursor protein. Am. J. Physiol. Heart Circ. Physiol. 283:H315–323.
Niwa, K., Porter, V. A., Kazama, K., Cornfield, D., Carlson, G. A., and Iadecola, C. (2001). Abeta-peptides enhance vasoconstriction in cerebral circulation. Am. J. Physiol. Heart Circ. Physiol. 281:H2417-H2424.
Niwa, K., Younkin, L., Ebeling, C., Turner, S. K., Westaway, D., Younkin, S., Ashe, K. H., Carlson, G. A., and Iadecola, C. (2000b). Abeta 1–40-related reduction in functional hyperemia in mouse neocortex during somatosensory activation. Proc. Natl. Acad. Sci. U.S.A. 97:9735–9740.
Price, D. L., and Sisodia, S. S. (1998). Mutant genes in familial Alzheimer's disease and transgenic models. Annu. Rev. Neurosci. 21:479–505.
Prohovnik, I., Mayeux, R., Sackeim, H. A., Smith, G., Stern, Y., and Alderson, P. O. (1988). Cerebral perfusion as a diagnostic marker of early Alzheimer's disease. Neurology 38:931–937.
Reiman, E. M., Caselli, R. J., Chen, K., Alexander, G. E., Bandy, D., and Frost, J. (2001). Declining brain activity in cognitively normal apolipoprotein E varepsilon 4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 98:3334–3339.
Selkoe, D. J. (2001). Alzheimer's disease: Genes, proteins, and therapy. Physiol. Rev. 81:741–766.
Shimohama, S., Tanino, H., Kawakami, N., Okamura, N., Kodama, H., Yamaguchi, T., Hayakawa, T., Nunomura, A., Chiba, S., Perry, G., Smith, M. A., and Fujimoto, S. (2000). Activation of NADPH oxidase in Alzheimer's disease brains. Biochem. Biophys. Res. Commun. 273:5–9.
Simonian, N. A., and Coyle, J. T. (1996). Oxidative stress in neurodegenerative diseases. Annu. Rev. Pharmacol. Toxicol. 36:83–106.
Small, G. W., Ercoli, L. M., Silverman, D. H., Huang, S. C., Komo, S., Bookheimer, S. Y., Lavretsky, H., Miller, K., Siddarth, P., Rasgon, N. L., Mazziotta, J. C., Saxena, S., Wu, H. M., Mega, M. S., Cummings, J. L., Saunders, A. M., Pericak-Vance, M. A., Roses, A. D., Barrio, J. R., and Phelps, M. E. (2000). Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 97:6037–6042.
Smith, C. D., Andersen, A. H., Kryscio, R. J., Schmitt, F. A., Kindy, M. S., Blonder, L. X., and Avison, M. J. (1999). Altered brain activation in cognitively intact individuals at high risk for Alzheimer's disease. Neurology 53:1391–1396.
Smith, M. A., Richey, H. P., Sayre, L. M., Beckman, J. S., and Perry, G. (1997). Widespread peroxynitrite-mediated damage in Alzheimer's disease. J. Neurosci. 17:2653–2657.
Stewart, R., Cai, H., Harrison, D. G., Rothe, G., and Valet, G. (1998). Cardiovascular factors in Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry. 65:143–147
Thomas, T., Thomas, G., McLendon, C., Sutton, T., and Mullan, M. (1996). ß-Amyloid-mediated vasoactivity and vascular endothelial damage. Nature 380:168–171.
Vinters, H. V., Wang, Z. Z., and Secor, D. L. (1996). Brain parenchymal and microvascular amyloid in Alzheimer's disease. Brain Pathol. 6:179–195.
Wilson, C. A., Doms, R. W., and Lee, V. M. (1999). Intracellular APP processing and A beta production in Alzheimer disease. J. Neuropathol. Exp. Neurol. 58:787–794.
Wolin, M. S. (2000). Interactions of oxidants with vascular signaling systems. Arterioscler Thromb. Vasc. Biol. 20:1430–1442.
Yan, S. D., Chen, X., Fu, J., Chen, M., Zhu, H., Roher, A., Slattery, T., Zhao, L., Nagashima, M., Morser, J., Migheli, A., Nawroth, P., Stern, D., and Schmidt, A. M. (1996). RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 382:685–691.
Zhang, F., Eckman, C., Younkin, S., Hsiao, K. K., and Iadecola, C. (1997). Increased susceptibility to ischemic brain damage in transgenic mice overexpressing the amyloid precursor protein. J. Neurosci. 17:7655–7661.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Iadecola, C. Cerebrovascular Effects of Amyloid-ß Peptides: Mechanisms and Implications for Alzheimer's Dementia. Cell Mol Neurobiol 23, 681–689 (2003). https://doi.org/10.1023/A:1025092617651
Issue Date:
DOI: https://doi.org/10.1023/A:1025092617651